CJC 1295 no/DAC 10mg

Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent
increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated,
particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after
multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent. CJC1295 increased trough and mean GH secretion and IGF-I production with preserved GH
pulsatility. The marked enhancement of through GH levels by continuous GHRH stimulation
implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may
have clinical utility in patients with intact pituitary GH secretory capability.
Reference:
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation
of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting
analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-
805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.